ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022.
Is ChemoCentryx a good investment?
ChemoCentryx has received a consensus rating of Buy The company’s average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Will ChemoCentryx go back up?
If you are looking for stocks with good return, ChemoCentryx Inc can be a profitable investment option. ChemoCentryx Inc quote is equal to 23.400 USD at 2022-05-29. Based on our forecasts, a long-term increase is expected , the “CCXI” stock price prognosis for 2027-05-21 is 39.882 USD.
Will CCXI stock go up?
The 8 analysts offering 12-month price forecasts for ChemoCentryx Inc have a median target of 64.50, with a high estimate of 106.00 and a low estimate of 34.00. The median estimate represents a +157.49% increase from the last price of 25.05.
Will ChemoCentryx get fda approval?
ChemoCentryx scores first FDA approval in 24-year history , and CEO Schall sees a blockbuster in the making. Five months ago, when the FDA raised multiple concerns over ChemoCentryx’s filing for a drug to treat vasculitis, the company’s stock plummeted.
Did CCXI get FDA approval?
Oct 8 (Reuters) – ChemoCentryx Inc (CCXI. O) said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease , sending the biopharmaceutical company’s shares up by more than 70%.
Should I hold CCXI?
Out of 4 analysts, 2 (50%) are recommending CCXI as a Strong Buy, 1 (25%) are recommending CCXI as a Buy, 1 (25%) are recommending CCXI as a Hold , 0 (0%) are recommending CCXI as a Sell, and 0 (0%) are recommending CCXI as a Strong Sell.
When did Ccxi go public?
MOUNTAIN VIEW, Calif. , Feb. 13, 2012 /PRNewswire/ — ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the completion of its initial public offering of 4,500,000 shares of common stock.
Who makes Tavneos?
08, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil.
Is avacopan available?
The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, alongside standard therapy , according to a press release. Source: Adobe Stock.
What is avacopan used for?
This medication is used to treat a certain type of blood vessel disease: anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis It works by blocking the immune system from damaging the blood vessels.
Citations
https://money.cnn.com/quote/forecast/forecast.html?symb=CCXI
https://walletinvestor.com/stock-forecast/ccxi-stock-prediction
